TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06757634: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Sponsor: Celcuity Inc · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1180 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT06757634 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06757634 Rescue Dossier →